The RDIF finances the production of Sputnik V in Russia using the manufacturing capacity of its portfolio companies, R-Pharm and Binnopharm (part of the Alium Group), and actively cooperates with more than 14 countries producing our vaccine abroad, including India, China, Brazil, Mexico, Egypt, Iran, Italy, South Korea, Argentina, Kazakhstan, the Republic of Belarus, Serbia, Turkey, Vietnam, etc.
The RDIF is successfully conducting Phase 3 clinical trials in 4 countries: Belarus, the UAE, India and Venezuela. Sputnik V has been approved for use in 70 countries with a total population of 4 billion people.
Vaccination with Sputnik V is underway in more than 50 countries on 4 continents, including Argentina, Hungary, Bolivia, Algeria, Montenegro, Paraguay, etc.
Message has been successfully sent!